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Hypertensive disorders of pregnancy (HDP) is one of the most 
common medical complications of pregnancy, affecting ~8% of all 
pregnancies. Two hospital-based studies in sub-Saharan Africa put 
the prevalence of this disorder at 11.5% and 26.5%, respectively.[1] 
It remains one of the most direct causes of maternal morbidity and 
mortality. HDP is classified into chronic hypertension, gestational 
hypertension, pre-eclampsia and eclampsia. Despite clinical remission 
in most instances (the exception being chronic hypertension), with 
blood pressure usually decreasing to normal within 6 weeks,[2] there 
is no structured follow-up programme for these women in South 
Africa (SA). 
It is now abundantly clear that healthy women who develop 
pre-eclampsia are more likely to develop hypertension at a younger 
age (30 - 40 v. 50 - 60 years), have an up to 4-fold increased risk 
of cardiovascular disease, and are more likely to develop stroke, 
myocardial infarction, atrial fibrillation and end-stage chronic kidney 
disease (ESKD).[3-6]
The mechanism underlying this association remains unclear.[7] 
There are two competing hypotheses. Firstly, HDP reflects an 
underlying genetic/environmental predisposition to hypertension 
that is uncovered during pregnancy and predicts future risk. This 
is akin to gestational diabetes and future diabetes where hormonal 
changes in pregnancy unmask this predisposition.
The second and possibly a more important hypothesis is that in 
women who have had pre-eclampsia there is consistent evidence 
of a residual degree of vascular dysfunction postpartum.[8] This 
undermines future vascular and renal function, resulting in an 
excess of cardiovascular and renal disease. Mechanisms underlying 
residual vascular damage are complex and involve, e.g. endothelin, 
angiotensin II, oxidative stress and inflammation, which may also 
interact with traditional risk factors for vascular disease.
There are few data regarding the prevalence of ESKD in SA 
following HDP. With this in mind, we conducted a retrospective 
study of women presenting to the renal assessment meetings at 
Groote Schuur Hospital, Cape Town, SA, for long-term dialysis to 
determine the prevalence of HDP and compare these women with 
those without this history.
Methods
This was a retrospective study performed on female patients with 
stage 5 chronic kidney disease (CKD), who were presented to renal 
replacement meetings at Groote Schuur Hospital between 2007 
and 2017. Patients returning to the renal replacement programme 
after a failed transplant were excluded. For each patient there was 
a comprehensive letter detailing demographics, psychosocial status, 
medical history and causes of CKD. This served as the source data. The 
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diabetic (1.4 v. 20.9%; p<0.001) or HIV-positive (2.9 v. 12.5%; p=0.019). There were no ethnic differences between patients and controls. 
Underlying causes of renal disease showed significant differences, as patients were more likely to have hypertensive nephropathy (57.1 v. 
22.9%; p<0.0001), and less likely to have diabetic kidney disease (1.4 v. 20.4%; p<0.001), HIV-associated nephropathy (HIVAN) (1.4 v. 6.4%) 
or polycystic kidney disease (1.4 v. 7.0%). There was no difference in acceptance to the dialysis and transplant programme (53 v. 47%). 
Conclusions. This study suggests an important link between hypertension in pregnancy and ESKD. The patients were significantly younger, 
presented later and were more likely to have hypertensive nephropathy. Methamphetamine abuse appears to be a risk factor. The study 
suggests that all women with hypertensive disorders during pregnancy need further evaluation and follow-up postpartum.
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causes of kidney disease were divided into hypertensive nephropathy, 
chronic glomerulonephritis (CGN), autosomal dominant polycystic 
kidney disease (ADPCKD), diabetic kidney disease, HIV-associated 
nephropathy and miscellaneous. This information was obtained 
from a detailed report by the referring doctor in consultation with 
the consulting nephrologist and a detailed psychosocial review 
by an experienced social worker. Patients whose report indicated 
a history of HDP were identified as the case group and those 
without such history were the control group. HDP was classified 
into chronic hypertension, gestational hypertension, pre-eclampsia, 
eclampsia, or undefined if there was insufficient information in the 
assessment letter. Acceptance into the programme was based on 
criteria developed by the Western Cape Provincial Government.[9]
Results were analysed using basic statistical tests – Pearson’s χ2, 
Fisher’s exact (2-sided) and 2-sample Wilcoxon rank-sum (Mann-
Whitney) tests.
Ethical approval
The study was approved by the Health Sciences Research Ethics 
Committee of the University of Cape Town (ref. no. 422/2017), and 
formed part of a student study module for 3rd-year medical students. 
Results 
Of the 415 female patients with ESKD, 70 (16.9%) had a history 
of hypertension in pregnancy. The causes of the latter were as 
follows: eclampsia (n=1; 1.4%), pre-eclampsia (n=26; 37.1%), gestational 
hypertension (n=11; 15.7%) and undefined (n=32; 45.7%). 
Compared with the control group, the patients were younger, with 
a median age of 33 v. 41 years (p<0.001), higher serum creatinine of 
1 045 v. 751 µmol/L (p=0.017) and lower estimated glomerular filtration 
rate (eGFR) of 4 v. 5.1 mL/min (p=0.029) (Table 1). Patients were 
more likely to abuse methamphetamine (5.7 v. 1.7%; p=0.049), 
and less likely to be diabetic (1.4 v. 20.9%; p<0.001) or HIV-
positive (2.9 v. 12.5%; p=0.019). Underlying causes of renal disease 
showed significant differences, as patients were more likely to have 
hypertensive nephropathy (57.1 v. 22.9%; p<0.0001), and less likely to 
have diabetic kidney disease (1.4 v. 20.3%; p<0.0001), HIV-associated 
nephropathy (HIVAN) (1.4 v. 6.4%) or polycystic kidney disease 
(1.4 v. 7.0%). Six renal biopsies were available in case groups – 4 in 
the CGN group showed focal segmental glomerulosclerosis, IgA 
nephropathy (n=2) and mesangial capillary glomerulonephritis; 2 in 
the hypertensive nephropathy group showed malignant hypertension, 
and 1 showed cortical necrosis. There was no difference in acceptance 
to the dialysis and transplant programme between patients and 
controls, respectively (53 v. 47%). 
Discussion
This small retrospective study is the first to examine the prevalence of 
HDP in female patients with ESKD in SA. The prevalence was found 
to be 16.9%, with a relative risk of 4.2 compared with patients without 
HDP. The patient demographics, medical histories and causes of 
ESKD were also significantly different from those of the controls. 
In summary, the patients were younger, more likely to present later, 
abuse methamphetamines and have hypertensive nephrosclerosis, 
but less likely to be HIV-positive or diabetic, and fewer had HIVAN, 
diabetic kidney disease or polycystic kidney disease as the underlying 
cause of their kidney disease. 
This is in agreement with previous studies of HDP where pre-
eclampsia during a first pregnancy was associated with a relative risk 
of ESKD of 4.7, but the absolute risk was small: 14.5 per 100 000 popu-
lation in a study from Norway.[4] In a study in the UK, the number 
of ESKD events in normotensive patients’ first pregnancy was 3.9%, 
gestational hypertension 5.2% and pre-eclampsia 7.5%.[3] However, 
these studies did not report the underlying cause of ESKD. 
The current study suggests that there is a significant unmet need 
for women with HDP. As we only studied patients with ESKD, our 
figures represent the tip of the iceberg. Many women have a lesser 
degree of CKD and are at risk of progression of their kidney disease. 
As the underlying cause was hypertensive nephrosclerosis, it suggests 
that this form of ESKD is preventable with earlier intervention. 
This is especially important in SA, where >50% of these young 
women did not qualify for dialysis owing to lack of resources. We 
recommend that women with HDP should undergo regular follow-
up postpartum for early detection and treatment of hypertension and 
CKD and screening for methamphetamine abuse. The association 
of methamphetamine and CKD has previously been documented by 
our group[10] – a service to establish this association is being planned 
at our hospital.
Study limitations
One of the limitations of the study was that we were unable to classify 
the HDP in 45.7% of cases, and were therefore unable to determine 
the effects of gestational hypertension, pre-eclampsia and chronic 
hypertension on ESKD. However, a recent publication has shown 
that both gestational hypertension and pre-eclampsia are associated 
with ESKD.[11] A second limitation was that we assessed only women 
Table 1. Demographic data of patients and controls
Patients (n=70) Controls (n=345) p-value
Median age, years 33 (IR 28 - 41) 41 (IR 31.5 - 48.0) <0.001
Median creatinine, µmol/L 1 045 (IR 573 - 1 585) 751 (489 - 1 245) 0.017
Median eGFR, mL/min 4 (IR 2 - 7) 5.1 (3 - 9) 0.029
BMI, kg/m2 25.8 (IR 23.0 - 31.1) 26 (IR 22.7 - 31.1) 0.261
Methamphetamine use, n (%) 4 (5.7) 2 (1.7) 0.049
Diabetic, n (%) 1 (1.4) 72 (20.9) <0.002
HIV-positive, n (%) 2 (2.9) 43 (12.5) 0.019
HPT nephropathy, n (%) 40 (57.1) 79 (22.9) <0.00001
CGN, n (%) 15 (21.4) 80 (23.2) 0.74
Diabetic kidney disease, n (%) 1 (1.4) 70 (20.3) <0.0001
HIVAN, n (%) 1 (1.4) 22 (6.4) 0.1
ADPKD, n (%) 1 (1.4) 24 (7.0) 0.09
IR = interquartile range; eGFR = estimated glomerular filtration rate; BMI = body mass index; HPT = hypertensive; CGN = chronic glomerulonephritis; HIVAN = HIV-associated nephropathy; 
ADPKD = autosomal dominant polycystic kidney disease. 
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who were presented to the renal replacement meetings; those with 
outright exclusion criteria, such as age >60 years, were not included. 
A third limitation was the retrospective design, but all records of 
patients presented during this period were captured. Furthermore, 
a comprehensive medical and psychosocial assessment that included 
a formal report by an experienced social worker was undertaken in 
every case and it is unlikely that there are significant missing data.
Conclusions
This study suggests an important link between hypertension in 
pregnancy and CKD. These patients are significantly younger, 
present later and are more likely to have hypertensive nephropathy. 
Methamphetamine abuse appears to be a risk factor. Further investi-
gation is warranted, but the study suggests that all women with HDP 
need further evaluation and should be followed up postpartum.
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